Although more and more evidence has showed that sigma-2 ligands have the ability to treat cancer and Alzheimer’s disease (AD), the mechanisms connecting these two diseases are unknown. This evidence concerns the gene AP2S1 and early-onset autosomal dominant Alzheimer disease.